

Title (en)  
CYTOKINE RECEPTOR TARGETED MOLECULES FOR TREATMENT OF MEOPLASTIC CELL GROWTH.

Title (de)  
GEGEN DEN CYTOKIN-REZEPTOR GERICHTETE MOLEKÜLE ZUR BEHANDLUNG DES NEOPLASMATISCHEN ZELLWACHSTUMS.

Title (fr)  
MOLECULES CIBLEES SUR UN RECEPTEUR DE CYTOKINE PAR LE TRAITEMENT DE LA CROISSANCE DE CELLULES NEOPLASIQUES.

Publication  
**EP 0584251 A4 19950802 (EN)**

Application  
**EP 92912726 A 19920515**

Priority  
US 70193291 A 19910517

Abstract (en)  
[origin: WO9220364A1] The invention features a method for treating meoplastic cell growth in a patient, wherein the meoplastic cell is of non-lymphoid and non-monocytic origin. The method includes administering to the patient a molecule which is capable of specifically binding to a cytokine receptor expressed on the meoplastic cell, which molecule is capable of decreasing the viability of the meoplastic cell. The cytokine receptor is a receptor normally expressed on cells of lymphoid or monocytic origin.

IPC 1-7  
**A61K 37/02**; **A61K 37/24**

IPC 8 full level  
**A61K 38/00** (2006.01); **A61K 39/395** (2006.01); **A61K 47/48** (2006.01); **A61P 35/00** (2006.01); **C07K 14/245** (2006.01); **C07K 14/34** (2006.01); **C07K 14/54** (2006.01); **C07K 14/55** (2006.01); **C07K 19/00** (2006.01)

CPC (source: EP)  
**A61K 47/62** (2017.07); **A61K 47/6813** (2017.07); **A61P 35/00** (2017.12); **C07K 14/245** (2013.01); **C07K 14/34** (2013.01); **C07K 14/5406** (2013.01); **C07K 14/5412** (2013.01); **C07K 14/55** (2013.01); **C07K 19/00** (2013.01); **A61K 38/00** (2013.01); **C07K 2319/00** (2013.01); **C07K 2319/55** (2013.01); **C07K 2319/75** (2013.01)

Citation (search report)

- [X] WO 9102000 A1 19910221 - SERAGEN INC [US]
- [X] WO 9101004 A1 19910124 - SERAGEN INC [US]
- [XP] WO 9119745 A1 19911226 - UNIV HOSPITAL [US]
- [X] CHARLES F. LEMAISTRE ET AL.: "THERAPEUTIC EFFECTS OF GENETICALLY ENGINEERED TOXIN (DAB486IL-2) IN PATIENT WITH CHRONIC LYMPHOCYTIC LEUKAEMIA.", LANCET THE, vol. 337, 11 May 1991 (1991-05-11), LONDON GB, pages 1124 - 1125
- [Y] TESUYUKI KIYOKAWA ET AL.: "PROTEIN ENGINEERING OF DIPHTHERIA-TOXIN-RELATED INTERLEUKIN-2 FUSION TOXINS TO INCREASE CYTOTOXIC POTENCY FOR HIGH-AFFINITY IL-2-RECEPTOR-BEARING TARGET CELLS.", PROTEIN ENGINEERING, vol. 4, no. 4, ENGLAND GB, pages 463 - 468
- [X] DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; & C. F. LEMAISTRE ET AL.: "PHASE I-II EVALUATION OF AN IL-2 RECEPTOR TARGETED FUSION TOXIN DAB-486 IL-2 FOR TREATMENT OF AIDS-ASSOCIATED KAPOSI'S SARCOMA.", ISITITUTO SUP. DI SANITA. VII INTERNATIONAL CONFERENCE ON AIDS: SCIENCE CHALLENGING AIDS; FLORENCE, ITALY, 16 June 1991 (1991-06-16), pages 79
- [X] NICHOLS, J. C. ET AL: "Development of IL-2-toxin ( DAB486 -IL-2) for human clinical trials in interleukin -2 receptor positive malignancies", ZENTRALBL. BAKTERIOL., SUPPL. (1990), 19(BACT. PROTEIN TOXINS), 479-87 CODEN: ZBASE2
- [X] BACHA, PATRICIA A. ET AL: "Impact of interleukin -2- receptor -targeted cytotoxins on a unique model of murine interleukin -2- receptor - expressing malignancy", INT. J. CANCER (1991), 49(1), 96-101 CODEN: IJCNAA;ISSN: 0020-7136
- See references of WO 9220364A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

DOCDB simple family (publication)  
**WO 9220364 A1 19921126**; CA 2103258 A1 19921118; EP 0584251 A1 19940302; EP 0584251 A4 19950802; JP H06507900 A 19940908

DOCDB simple family (application)  
**US 9204093 W 19920515**; CA 2103258 A 19920515; EP 92912726 A 19920515; JP 50021493 A 19920515